Latest Mapatumumab Stories
Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone.
For the first time to date, research published in the October edition of the Journal of Thoracic Oncology (JTO) sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages.
MONTREAL and HONG KONG, China, July 19 /PRNewswire/ - Aegera Therapeutics Inc.
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center.
The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer (NSCLC).
Perifosine demonstrated to be safe and tolerable, with early signs of clinical benefit in advanced refractory pediatric neuroblastoma patients QUEBEC CITY, June 7 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
CHICAGO, June 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
CHICAGO, June 6 /PRNewswire/ -- Alder Biopharmaceuticals Inc.
CALGARY, May 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has opened enrollment in its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.